What is HC Wainwright’s Forecast for ONCY FY2027 Earnings?
Investment analysts at HC Wainwright boosted their FY2027 EPS estimates for shares of Oncolytics Biotech in a research report ...
Leede Financial Issues Positive Outlook for TSE:ONC Earnings
Equities research analysts at Leede Financial boosted their FY2025 earnings per share (EPS) estimates for shares of ...
Oncolytics Biotech: Continuing To Justify The Negativity
Oncolytics Biotech faces financial struggles and unclear pelareorep efficacy signals. Learn why ONCY stock's risks outweigh ...
TipRanks on MSN6d
Oncolytics Biotech’s Financial Stability at Risk: Urgent Need for New Financing
Oncolytics Biotech (ONCY) has disclosed a new risk, in the Corporate Activity and Growth category. Oncolytics Biotech faces significant business ...
Yahoo Finance10d
Oncolytics Biotech (ONCY) Loses -9.34% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Oncolytics Biotech Inc. (ONCY) has been beaten down lately with too much selling pressure. While the stock has lost 9.3% over the past four weeks, there is light at the end of the tunnel as it is ...
Oncolytics price target lowered to $3 from $5 at Maxim
Maxim lowered the firm’s price target on Oncolytics (ONCY) to $3 from $5 and keeps a Buy rating on the shares. The firm is adjusting its model ...
Oncolytics Biotech® Reports Highlights and Financial Results for Q4 and Year-End 2024
CNW/ -- (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today ...
Oncolytics price target lowered to C$5 from C$6 at RBC Capital
RBC Capital lowered the firm’s price target on Oncolytics (ONCY) to C$5 from C$6 and keeps an Outperform rating on the shares.Optimize Your ...
From Clinical Trials to the Market: Cancer Stocks With Big Potential in 2025
USA News Group News Commentary – As cancer rates continue to climb worldwide, the push for innovative treatments has never ...